98%
921
2 minutes
20
Aim: Clinical registries are an important research tool to enhance our understanding of vision loss in the Australian paediatric population. We aim to provide an update on the epidemiology of visual impairment among Western Australian children using registry data analysis, and to highlight the challenges of registry data collection.
Methods: This is a retrospective study of visual impairment and blindness registrations of children aged 0-16 years in Western Australia from 1996 to 2015. Blindness was defined as visual acuity ≤6/60 in the better-seeing eye or binocular visual field ≤20° diameter, with all other certifications labelled as visual impairment. Certificates were assessed for primary causes of vision loss by age strata and sex. Registration rate trends were analysed across three discrete registration periods.
Results: Of 11 800 certificates issued between 1996 and 2015, 728 certificates (6.2%) were issued to 710 children. Five hundred and twenty-nine (74.5%) certificates were issued for visual impairment and 181 (25.5%) for blindness. The leading cause of certification was inherited retinal disease (73, 10.3%), followed by cortical visual impairment (57, 8.0%) and albinism (56, 7.9%). The annual registration rate of visual impairment increased from 0.5 to 9.8 per 100 000 person-years across the study period, whereas blindness rates fell from 2.7 to 1.3.
Conclusions: Overall registration rates of paediatric visual impairment in Western Australia are increasing, but these trends should be interpreted with caution given the known limitations of registry data. Enhancements of the registration process could be achieved through digitisation, inclusion of patient outcome data, and incentives for greater practitioner engagement.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jpc.16709 | DOI Listing |
Ann Acad Med Singap
August 2025
Dementia Research Centre (Singapore), Lee Kong Chian School of Medicine, Nanyang Technology University, Singapore.
Introduction: Interpretation and analysis of magnetic resonance imaging (MRI) scans in clinical settings comprise time-consuming visual ratings and complex neuroimage processing that require trained professionals. To combat these challenges, artificial intelligence (AI) techniques can aid clinicians in interpreting brain MRI for accurate diagnosis of neurodegenerative diseases but they require extensive validation. Thus, the aim of this study was to validate the use of AI-based AQUA (Neurophet Inc.
View Article and Find Full Text PDFOphthalmic Plast Reconstr Surg
September 2025
Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California, U.S.A.
Purpose: To evaluate the efficacy and safety of teprotumumab for the treatment of thyroid eye disease in geriatric patients.
Methods: This was a multicenter cohort study of patients aged 75 and older, treated between February 2020 and September 2023 across 10 tertiary institutions. Patients were included if they had moderate-to-severe thyroid eye disease and at least 1 infusion of teprotumumab.
Adv Mater
September 2025
Key Laboratory of Brain-Like Neuromorphic Devices and Systems of Hebei Province, College of Electronic and Information Engineering, Hebei University, Baoding, 071002, China.
Neuromorphic Visual Devices hold considerable promise for integration into neuromorphic vision systems that combine sensing, memory, and computing. This potential arises from their synergistic benefits in optical signal detection and neuro-inspired computational processes. However, current devices face challenges such as insufficient light/dark resistance ratios, mismatched transient photo-response, and volatile retention characteristics, limiting their adaptability to complex artificial vision systems.
View Article and Find Full Text PDFOphthalmic Physiol Opt
September 2025
Division of Occupational Therapy and Physical Therapy, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Purpose: Cerebral Visual Impairment (CVI) is the leading cause of paediatric visual impairment in developed countries. Earlier diagnosis provides access to early intervention, which may improve visual function, functional vision and developmental outcomes. The purpose of this study was to determine the age and timing of CVI diagnosis and the severity of CVI.
View Article and Find Full Text PDFFront Cell Neurosci
August 2025
Stem Cell Research Center, University of California, Irvine, Irvine, CA, United States.
Objective: To assess the safety and tolerability of intravitreal injection of human retinal progenitor cells (RPCs) at multiple dose levels in adults with non-syndromic retinitis pigmentosa (RP).
Design: A prospective, multicenter, open-label, single-arm, Phase I/IIa safety study of RPCs in adults with RP ( = 28). Two patient cohorts were studied: Cohort 1: BCVA no better than 20/200 and no worse than Hand Motions, and Cohort 2: BCVA no better than 20/40 and no worse than 20/200).